Who is sponsoring NCT02926170?

NCT02926170 is sponsored by Hospital Universitari Vall d'Hebron Research Institute.

What condition does NCT02926170 study?

NCT02926170 studies Antiphospholipid Syndrome.

What drugs are being tested in NCT02926170?

Interventions: Rivaroxaban, acenocumarol.

What is the status of NCT02926170?

NCT02926170 is currently COMPLETED.

Last reviewed 2018-05-11 · How we verify

Rivaroxaban for Patients With Antiphospholipid Syndrome

NCT02926170 PHASE3 COMPLETED

Long-term anticoagulation is widely used for secondary thromboprophylaxis in the antiphospholipid syndrome (APS) due to the high risk of recurrent events. Currently anticoagulation with vitamin K antagonists (VKAs) is the standard of care but have unpredictable pharmacodynamic properties that requiere monitoring for dose adjustment. Rivaroxaban, an orally active direct factor Xa inhibitor, has been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism and non valvular atrial fibrillation in major RCTs. No studies had been published in APS.The aim of the study is to investigate the efficacy and safety of rivaroxaban in preventing recurrent thrombosis in patients with APS compared with acenocoumarol

Details

Lead sponsor	Hospital Universitari Vall d'Hebron Research Institute
Phase	PHASE3
Status	COMPLETED
Enrolment	190
Start date	Wed Mar 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Antiphospholipid Syndrome

Interventions

Rivaroxaban
acenocumarol

Countries

Spain